Filters

Term Search
You can select from the dropdown list OR enter your own terms to refine the search.

Last Updated: 10/31/2025

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13550 publications

Sorafenib generates microvesicle particles in non-small cell lung cancer.

Sorafenib generates microvesicle particles in non-small cell lung cancer.

Journal: Tumor discovery
Published: October 17, 2025

Corrigendum to "Sorafenib in patients with locally advanced and metastatic chordomas: a phase II trial of the French Sarcoma Group (GSF/GETO)": [Ann Oncol 26 (2015) 2168-2173].

Corrigendum to "Sorafenib in patients with locally advanced and metastatic chordomas: a phase II trial of the French Sarcoma Group (GSF/GETO)": [Ann Oncol 26 (2015) 2168-2173].

Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: October 16, 2025

Real-world treatment adherence and persistence of FLT3 inhibitors as post-alloHCT maintenance therapy in patients with AML in the United States: a cohort study using administrative claims data.

Real-world treatment adherence and persistence of FLT3 inhibitors as post-alloHCT maintenance therapy in patients with AML in the United States: a cohort study using administrative claims data.

Journal: Leukemia & lymphoma
Published: October 03, 2025

Lipid-Extruded PEGylated Liposomes of Repurposed Sorafenib for Triple-Negative Breast Cancer: A Mechanistically Enhanced Nanoplatform with Improved In Vivo Pharmacokinetics and Targeted Biodistribution.

Lipid-Extruded PEGylated Liposomes of Repurposed Sorafenib for Triple-Negative Breast Cancer: A Mechanistically Enhanced Nanoplatform with Improved In Vivo Pharmacokinetics and Targeted Biodistribution.

Journal: ACS applied bio materials
Published: September 30, 2025

miR-199a-5p/GPR89A axis modulates sorafenib resistance in hepatocellular carcinoma through glutamate metabolic reprogramming.

miR-199a-5p/GPR89A axis modulates sorafenib resistance in hepatocellular carcinoma through glutamate metabolic reprogramming.

Journal: Science progress
Published: September 23, 2025

Fluorinated Proteolysis Targeting Chimeras-Sorafenib Nanoassembly for Epigenetic Remodeling to Combat Multi-Pathway Drug Resistance in Hepatocellular Carcinoma.

Fluorinated Proteolysis Targeting Chimeras-Sorafenib Nanoassembly for Epigenetic Remodeling to Combat Multi-Pathway Drug Resistance in Hepatocellular Carcinoma.

Journal: ACS nano
Published: September 22, 2025

Erratum: MiR-374b re-sensitizes hepatocellular carcinoma cells to sorafenib therapy by antagonizing PKM2-mediated glycolysis pathway.

Erratum: MiR-374b re-sensitizes hepatocellular carcinoma cells to sorafenib therapy by antagonizing PKM2-mediated glycolysis pathway.

Journal: American journal of cancer research
Published: September 19, 2025

Retraction notice to "A novel PEGylated squid-derived protamine protein in combination with sorafenib effectively inhibits hepatocellular carcinoma growth" [Int. J. Biol. Macromol. 319 (2025) 145283].

Retraction notice to "A novel PEGylated squid-derived protamine protein in combination with sorafenib effectively inhibits hepatocellular carcinoma growth" [Int. J. Biol. Macromol. 319 (2025) 145283].

Journal: International journal of biological macromolecules
Published: September 17, 2025

UC2288-Mediated Increased Osteogenic Expression in Mesenchymal Stem Cells.

UC2288-Mediated Increased Osteogenic Expression in Mesenchymal Stem Cells.

Journal: Stem cells and development
Published: September 15, 2025

Ecofriendly densitometric (RP and NP) HPTLC methods for determination of sorafenib in bulk and formulations.

Ecofriendly densitometric (RP and NP) HPTLC methods for determination of sorafenib in bulk and formulations.

Journal: Analytical methods : advancing methods and applications
Published: September 12, 2025

Protocol: Faecal microbiota transfer in liver cancer to overcome resistance to atezolizumab/bevacizumab - a multicentre, randomised, placebo-controlled, double-blind phase II trial (the FLORA trial).

Protocol: Faecal microbiota transfer in liver cancer to overcome resistance to atezolizumab/bevacizumab - a multicentre, randomised, placebo-controlled, double-blind phase II trial (the FLORA trial).

Journal: BMJ open
Published: September 10, 2025

Solvent-Directed Self-Assembly of Sorafenib into Spherical Particles for Enhanced Anticancer Efficacy.

Solvent-Directed Self-Assembly of Sorafenib into Spherical Particles for Enhanced Anticancer Efficacy.

Journal: Nano letters
Published: September 08, 2025
Showing 1-12 of 13,550

Last Updated: 10/31/2025